Literature DB >> 23689920

Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism.

Rodolfo Savica1, Brandon R Grossardt, James H Bower, J Eric Ahlskog, Walter A Rocca.   

Abstract

IMPORTANCE: The frequency and distribution of synucleinopathies and tauopathies manifesting with parkinsonism in the general population are poorly understood, thus affecting health care planning and research.
OBJECTIVE: To investigate the incidence and distribution of specific types of parkinsonism and related proteinopathies.
DESIGN: We used the medical records-linkage system of the Rochester Epidemiology Project to identify all subjects who received a screening diagnostic code related to parkinsonism in Olmsted County, Minnesota, from January 1, 1991, through December 31, 2005 (15 years). A movement disorders specialist reviewed the complete medical records of each subject who screened positive to determine the type of parkinsonism and the presumed proteinopathy using specified criteria.
SETTING: Geographically defined population. PARTICIPANTS: All residents of Olmsted County who provided authorization to use their data for medical records research (population-based sample). MAIN OUTCOME AND MEASURES: Incidence of parkinsonism and specific proteinopathies.
RESULTS: Among 542 incident cases of parkinsonism, 409 (75.5%) were classified as proteinopathies. Of the 389 patients with presumed synucleinopathies (71.8%), 264 had Parkinson disease (48.7% of all cases). The incidence rate of synucleinopathies was 21.0 per 100 000 person-years overall and increased steeply with age. The incidence rate of tauopathies was 1.1 overall (20 cases), and the most common tauopathy was progressive supranuclear palsy (16 cases). Thirty-six subjects had drug-induced parkinsonism (6.6%), 11 had vascular parkinsonism (2.0%), 1 had amyotrophic lateral sclerosis in parkinsonism (0.2%), 1 had parkinsonism secondary to surgery (0.2%), and 84 remained unspecified (15.5%). Men had a higher incidence than women for most types of parkinsonism. Findings at brain autopsy confirmed the clinical diagnosis in 53 of 65 patients who underwent autopsy (81.5%). CONCLUSIONS AND RELEVANCE: The incidence of proteinopathies related to parkinsonism increases steeply with age and is consistently higher in men than women. Clinically diagnosed synucleinopathies are much more common than tauopathies. Findings at autopsy confirm the clinical diagnosis of presumed proteinopathy. Our findings may guide health care planning and prompt new research directions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23689920      PMCID: PMC3707980          DOI: 10.1001/jamaneurol.2013.114

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  37 in total

1.  Risk tables for parkinsonism and Parkinson's disease.

Authors:  Alexis Elbaz; James H Bower; Demetrius M Maraganore; Shannon K McDonnell; Brett J Peterson; J Eric Ahlskog; Daniel J Schaid; Walter A Rocca
Journal:  J Clin Epidemiol       Date:  2002-01       Impact factor: 6.437

2.  Risk factors for Parkinson's disease may differ in men and women: an exploratory study.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Walter A Rocca
Journal:  Horm Behav       Date:  2012-06-08       Impact factor: 3.587

3.  Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca
Journal:  Int J Epidemiol       Date:  2012-11-18       Impact factor: 7.196

4.  Gender differences in Parkinson's disease symptom profile.

Authors:  B Scott; A Borgman; H Engler; B Johnels; S M Aquilonius
Journal:  Acta Neurol Scand       Date:  2000-07       Impact factor: 3.209

5.  Time trends in the incidence of parkinsonism in Olmsted County, Minnesota.

Authors:  W A Rocca; J H Bower; S K McDonnell; B J Peterson; D M Maraganore
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

6.  Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease.

Authors:  J H Bower; D M Maraganore; S K McDonnell; W A Rocca
Journal:  Mov Disord       Date:  2000-09       Impact factor: 10.338

7.  Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity.

Authors:  Stephen K Van Den Eeden; Caroline M Tanner; Allan L Bernstein; Robin D Fross; Amethyst Leimpeter; Daniel A Bloch; Lorene M Nelson
Journal:  Am J Epidemiol       Date:  2003-06-01       Impact factor: 4.897

Review 8.  Systematic review of incidence studies of Parkinson's disease.

Authors:  Dominique Twelves; Kate S M Perkins; Carl Counsell
Journal:  Mov Disord       Date:  2003-01       Impact factor: 10.338

9.  Clinical correlates of the pathology underlying parkinsonism: a population perspective.

Authors:  James H Bower; Dennis W Dickson; Laura Taylor; Demetrius M Maraganore; Walter A Rocca
Journal:  Mov Disord       Date:  2002-09       Impact factor: 10.338

10.  Are men at greater risk for Parkinson's disease than women?

Authors:  G F Wooten; L J Currie; V E Bovbjerg; J K Lee; J Patrie
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-04       Impact factor: 10.154

View more
  63 in total

Review 1.  Long Non-coding RNAs in Parkinson's Disease.

Authors:  Chengqi Xin; Jing Liu
Journal:  Neurochem Res       Date:  2021-02-05       Impact factor: 3.996

2.  Response to Letter by Friedman on "Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study".

Authors:  Walter A Rocca; Rodolfo Savica; Brandon R Grossardt
Journal:  Mov Disord       Date:  2017-06-14       Impact factor: 10.338

3.  Levodopa-induced dyskinesia in Parkinson disease: A population-based cohort study.

Authors:  Pierpaolo Turcano; Michelle M Mielke; James H Bower; Joseph E Parisi; Jeremy K Cutsforth-Gregory; J Eric Ahlskog; Rodolfo Savica
Journal:  Neurology       Date:  2018-11-07       Impact factor: 9.910

Review 4.  Vascular Parkinsonism: deconstructing a syndrome.

Authors:  Joaquin A Vizcarra; Anthony E Lang; Kapil D Sethi; Alberto J Espay
Journal:  Mov Disord       Date:  2015-05-21       Impact factor: 10.338

Review 5.  Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders.

Authors:  Shang-Yi A Tsai; Michael J Pokrass; Neal R Klauer; Nicole E De Credico; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2014-10-21       Impact factor: 6.902

6.  Survival and Progression in Synucleinopathy Phenotypes With Parkinsonism: A Population-Based Study.

Authors:  Rodolfo Savica; Pierpaolo Turcano; James H Bower; J Eric Ahlskog; Michelle M Mielke
Journal:  Mayo Clin Proc       Date:  2019-08-09       Impact factor: 7.616

7.  Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer.

Authors:  James W S Young; Rinku Sutradhar; Jagadish Rangrej; Connie Marras; Neil Fleshner; Shabbir M H Alibhai
Journal:  World J Urol       Date:  2017-02-15       Impact factor: 4.226

Review 8.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

9.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

10.  Incidence of dementia with Lewy bodies and Parkinson disease dementia.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; Bradley F Boeve; J Eric Ahlskog; Walter A Rocca
Journal:  JAMA Neurol       Date:  2013-11       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.